#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
CS
proLékaře.cz / Journals / Transfusion and Haematology Today / 2019 - Online only 1

Castleman disease, one of the causes of chronic systemic inflammatory response as well as fluid retention, vasculitis and immune disorders sometimes – international criteria, 2017

Czech version

Authors: Z. Král 1;  Z. Adam 1;  P. Volfová 2;  M. Ježová 3;  M. Krejčí 1;  L. Pour 1;  Z. Řehák 4,5;  R. Koukalová 4
Authors‘ workplace: Interní hematologická a onkologická klinika LF MU a FN Brno, Jihlavská 25, 625 00 Brno 1;  Interní hematologická a onkologická klinika – Centrum molekulární biologie a genové terapie, sekce oportunních infekcí, Dětská nemocnice, Černopolní 9, 625 00 Brno 2;  Ústav patologie LF MU a FN Brno, Jihlavská 25, 625 00 Brno 3;  Oddělení nukleární medicíny, Masarykův onkologický ústav, Žlutý kopec 7, 656 53, Brno 4;  Regionální centrum aplikované molekulární onkologie (RECAMO), Masarykův onkologický ústav, Žlutý kopec 7, 656 53, Brno 5
Published in: Transfuze Hematol. dnes,1, 2019, No. Online only 1, p. 1-15.
Category:

Overview

Castleman disease was first described more than 60 years ago. It is a rare and heterogenic group of diseases characterised by lymphadenopathy with typical morphological features associated with general inflammatory symptoms and laboratory deviations.

The first international diagnostic criteria of this disease were published in 2017 and are detailed in this article. In the USA, the incidence of this diseases is estimated at 5/1 million inhabitants. The incidence in the Czech Republic has not been determined as yet. However, it is possible that some cases are considered to represent a systemic inflammatory response of unknown origin and are thus not diagnosed properly. The aim of this text is to recapitulate the manifestations of this disease and present the first international diagnostic criteria published in 2017.

Keywords:

rituximab – thalidomide – Castleman disease – POEMS syndrome – TAFRO syndrome – lenalidomid – siltuximab – anakinra

Sources
  1. Dispenzieri A. Castleman disease. Cancer Treat Res 2008;142:293–330.
  2. Liu AY, Nabel CS, Finkelman BS, et al. Idiopathic multicentric Castleman's disease: a systematic literature review. Lancet Haematol 2016;3(4):e163–e175.
  3. Chan Kah-Lok, Lade S, Prince HM, et al. Update and new approaches  in the threatment of Castleman disease. J Blood Med 2016; 7:145–158.
  4. Fajgenbaum DC, Uldrick TS, Bagg A, et al. International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood 2017;129(12):1646–1657.
  5. Simpson D. Epidemiology of Castleman disease. Hematol Oncol Clin North Am 2018;32(1):1–10.
  6. Castleman B, Towe VW. Case report of the Massachusetts General Hospital weekly clinicopathological exercises, fouded by Richard C Cabot. N Engl J Med 1954;251(10):396–400.
  7. Keller AR, Hochholzer L, Castleman  B. Hyaline-vascular and  plasma-cell types of giant lymph node hyperplasia of the mediastinum and other localisation. Cancer 1972;29:670–683.
  8. Gaba AR Stein RS Sweet DJ, et al. Multicentric giant node hyperplasia. Amer J Clin Pathol 1978;69(1):86–90.
  9. Soulier J, Grollet L, Oksenhendler E, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 1995;86(4):1276–1280.
  10. Chadbum A, Cesarman E, Nador RG, et al. Kaposi´s sarcoma-associated herpesvirus sequences in benign lymphoid proliferations not associated with human immunodeficiency virus. Cancer 1997;80:788–797.
  11.  Riu P, Noesl LH, Droz D, et al. Glomerular involvement in lymfoproliferative disorders with hyperproduction of cytokines (Castleman, POEMS). Adv Nephrol Necke Hosp 2000;30:305–331.
  12. Masaki Y, Nakajima A, Iwao H, et al. Japanese variant of multicentric Castleman's disease associated with serositis and thrombocytopenia – a report of two cases: is TAFRO syndrome (Castleman-Kojima disease) a distinct clinicopathological entity? J Clin Exp Hematop 2013;53(1):79–85.
  13. Kawabata H, Takai K, Kojima M, et al. Castleman-Kojima disease (TAFRO syndrome): a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia, ascites (anasarca), microcytic anemia, myelofibrosis, renal dysfunction, and organomegaly. J Clin Exp Hematop 2013;53(1):57–61.
  14. Inoue M, Ankou M, Hua J, at al. Complete resolution of TAFRO syndrome (thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly) after immunosuppressive therapies using corticosteroids and cyclosporin A: a case report. J Clin Exp Hematop 2013;53(1):95–99.
  15.  Tedesco S, Postacchini L, Manfredi L, et al. Successful treatment of a Caucasian case of multifocal Castleman´s disease with TAFRO syndrome with pathophysiology targeted therapy – case report. Exp Hematol Oncol 2015;4(1):3–10.
  16. Masaki Y, Kawabata H, Takai K, et al. Proposed diagnostic criteria, disease severity classification and treatment stratedy for Tafro syndrome, 2015 version. Int J Hematol 2016;103:686–692.
  17. Robinson D Jr, Reynolds M, Casper C, et al. Clinical epidemiology and treatment patterns of patients with multicentric Castleman disease: results from two US treatment centres. Br J Haematol 2014;165(1):39–48.
  18. Fajgenbaum DC, vanRhee F, Nabel ChS. HHV-8 negative idiopathic multicentric Castleman disease: novel insight into biology pathogenesis and therapy. Blood 2014;123(19):2924–2933.
  19.  Bower M, Pria AD, Coyle C, et al. Diagnostic criteria schemes for multicentric Castleman disease in 75 cases. J Acquir Immune Defic Syndr 2014;65(2):e80–e82.
  20. Cronin DM, Warnke RA. Castleman disease: an update on classification and the spectrum of associated lesions. Adv Anat Pathol 2009;16:236–246.
  21.  Kawabata H, Kadowaki N, Nishikori M, et al. Clinical features and treatment of multicentric Castleman's disease: a retrospective study of 21 Japanese patients at a single institute. J Clin Exp Hematop 2013;53(1):69–77.
  22. El Karoui K, Vuiblet V, Dion D, et al. Renal involvement in Castleman disease. Nephrol Dial Transplant 2011;26(2):599–609.
  23. Sydor A, Madura M, Wagrowska-Danilewicz M. Amyloid A amyloidosis and renal failure in a course of Castleman disease. Nephrology (Carlton) 2007;12(6):620–621.
  24. Leung KT, Wong KM, Choi KS, et al Multiicentric Castleman's disease complicated by secondary renal amyloidosis. Nephrology (Carlton) 2004;9(6):392–393.
  25. Dispenzieri A. POEMS syndrome: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol 2014;89(2):214–223.
  26. Fajgenbaum DC, Rosenbach M, van Rhee F, et al. Eruptive cherry hemangiomatosis associated with multicentric Castleman disease: a case report and diagnostic clue. JAMA Dermatol 2013;149(2):204–208.
  27. Ruwan KP, Parakramawansha C, Wijeweera I, et al. A case of POEMS syndrome with mixed hyaline vascular and plasma cell type Castleman's disease. Ceylon Med J 2009;54(2):68–69.
  28. Misri R, Kharkar V, Dandale A, et al. Multiple capillary hemangiomas: a distinctive lesion of multicentric Castleman's disease and POEMS syndrome. Indian J Dermatol Venereol Leprol 2008;74(4):364–366.
  29. Garcia T, Dafer R, Hocker S, et al. Recurrent strokes in two patients with POEMS syndrome and Castleman's disease. J Stroke Cerebrovasc Dis 2007;16(6):278–284.
  30. Eisenbarth SC, Colegio OR, Iyer A, Cooper D, Bannykh S, Baehring J. Images in neuro-oncology: a case of POEMS (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal protein and Skin changes) in a patient with multicentric Castleman's disease. J Neurooncol 2007;81(2):163–165.
  31. Huang J, Wang L, Zhou W, Jin J. Hyaline vascular Castleman disease associated  with POEMS syndrome and cerebral infarction. Ann Hematol 86(1):59–61.
  32. Iwaki N, Fajgenbaum DC, Nabel SCh, et al. Clinicopathological analysis of Tafro syndrome demonstrates a distinct subtype of HHV-8 negative multicentric Castleman disease. Am J Hematol 2016;91:220–226.
  33. Igawa T, Sato Y. TAFRO Syndrome. Hematol Oncol Clin North Am 2018;32(1):107–118.
  34. Dispenzieri A, Armitage J O, Loes M J, et al. The clinical spectrum of Castleman´s disease. Amer J Hematol 2012;87:997–1002. 
  35.  Szalat R, Munshi NC. Diagnosis of Castleman disease. Hematol Oncol Clin North Am 2018;32(1):53–64.
  36. Van Rhee F, Voorhees P, Dispenzieri A, et al. International evidence based consensus  treatment guidelines for idiopahtic multicentric Castleman disease. Blood 2018;132(20):2115–2124.
Labels
Haematology Internal medicine Clinical oncology
Genome editing using the CRISPR/Cas9 system and its application in haematology
Thrombotic microangiopathies
Transformation of chronic lymphocytic leukaemia into Hodgkin lymphoma
Richter transformation of chronic lymphocytic leukemia in the era of treatment with B-cell signaling pathway inhibitors
Article was published in

Transfusion and Haematology Today

Issue Online only 1
2019 Issue Online only 1
Most read in this issue
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#